20-F: Quantum BioPharma Navigates Drug Development, Crypto Volatility

Quantum BioPharma Ltd. reports a net loss of $26.96 million for 2025, driven by R&D costs and significant cryptocurrency fair value adjustments, while advancing its MS drug and settling key litigation.

Summary

• Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) reported a net loss of $26,956,840 for the year ended December 31, 2025, an increase from $14,915,529 in 2024.
• Cash used in operating activities for 2025 was $8,237,012, compared to $6,876,479 in 2024.
• The company completed a 65:1 share consolidation and changed its name to Quantum BioPharma Ltd. on August 15, 2024.
• Biopharmaceutical operations focus on Lucid-MS for multiple sclerosis, which completed 90-day oral toxicity and toxicokinetic studies in 2025, supporting a future US FDA IND application for a Phase 2 trial.
• Positive Phase 1 Multiple Ascending Dose (MAD) clinical trial results for Lucid-MS in healthy participants were announced on August 5, 2025, showing the drug was safe and well-tolerated.
• The company is developing a healthcare product for alcohol misuse, requiring approximately $10,998,811 in funding for R&D and clinical trials, with non-clinical activities expected to commence in Q4 2026-Q3 2027.
• Unbuzzd, a consumer recreational beverage product for alcohol misuse, completed a double-blind, randomized, placebo-controlled crossover clinical trial (NCT06505239) in February 2025, demonstrating accelerated alcohol metabolism and reduced intoxication symptoms.
• The company sold its entire portfolio of residential mortgage loan receivables from its FSD Strategic Investments segment to a corporation owned by the CFO in 2025, realizing a loss of $117,136.
• Cryptocurrency holdings expanded in 2025 to include Bitcoin, Solana, Ethereum, Sui, and Chainlink, with net purchases of $3,726,073 during FY2025 and an aggregate of $7,082,773 as of the annual report date.
• An unrealized loss of $771,863 on digital assets was recorded in 2025, primarily due to a 30% drawdown of Bitcoin in Q4 2025.
• The company settled all outstanding litigation with former CEO Dr. Raza Bokhari in May 2025, receiving a one-time payment of $2,350,000, which was recorded as other income.
• A lawsuit seeking over $700 million in damages for alleged stock manipulation and 'spoofing' against CIBC World Markets, RBC Dominion Securities, and others is ongoing, with a motion to dismiss filed by defendants in June 2025.
• The company announced its intention to declare a special dividend of Contingent Value Rights (CVRs) to Class B shareholders, contingent on net settlement proceeds from the ongoing litigation exceeding $50,000,000.
• Total operating expenses decreased by 5% to $15,302,374 in 2025 from $16,136,260 in 2024, primarily due to a 55% reduction in external R&D fees, partially offset by a significant increase in share-based payments.
• Share-based payments increased significantly to $2,945,502 in 2025 from $152,214 in 2024, reflecting new option and RSU grants.
• The company issued convertible debentures in December 2024 and January 2025, raising aggregate gross proceeds of C$5,000,000, which were fully converted into Class B Subordinate Voting Shares by December 31, 2025.
• A loss on issuance of convertible debt of $1,490,278 was recognized in 2025 due to the fair value of warrants and conversion features exceeding the principal debt amount.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While there are positive clinical trial results for Lucid-MS and a significant litigation settlement, the substantial net loss, increased cash burn, and ongoing legal and financial risks, particularly from cryptocurrency volatility and the need for future capital raises, temper overall sentiment.

Positives

• Lucid-MS Phase 1 MAD clinical trial showed the drug was safe and well-tolerated with no identified safety concerns in healthy participants, a critical step for advancing to efficacy trials.
• Unbuzzd's clinical trial (NCT06505239) demonstrated statistically significant acceleration of blood alcohol concentration reduction and decreased symptoms of intoxication and hangover.
• Settlement of all outstanding litigation with former CEO Dr. Raza Bokhari resulted in a one-time payment of $2,350,000 to the company, resolving legal uncertainties and associated costs.
• The company expanded its cryptocurrency treasury, diversifying its financial assets with holdings in Bitcoin, Solana, Ethereum, Sui, and Chainlink.
• Health Canada granted a Product License (PN 80144141) for Qlarity, a natural health product similar to Unbuzzd, allowing its sale in Canada.
• Kingswood Capital Partners initiated unpaid coverage of Quantum BioPharma with a BUY rating and a US$45 price target, assuming successful Phase 2 and 3 trials of Lucid-MS and a 2029 commercial launch.
• The company secured an agreement with a Global Pharmaceutical Contract Research Organization to prepare an application for Lucid-MS, streamlining regulatory efforts.
• A joint clinical study with Massachusetts General Hospital (MGH) scientists is validating a novel PET imaging technique for monitoring myelin integrity in MS patients, potentially aiding Lucid-MS development.
• The company signed an agreement with a leading CDMO to manufacture an oral drug formulation of Lucid-MS for its Phase 2 clinical trial, indicating progress towards commercialization.
• The company benefited from Australian R&D tax credit initiatives, reducing research expenditures by approximately $1 million for Huge Biopharma and $870,000 for FSD Australia in FY2025.
• The company successfully sold $5,350,781 in proceeds under its at-the-market offering agreement with Rodman and Renshaw LLC subsequent to December 31, 2025.

Negatives

• The company reported a significant net loss of $26,956,840 for the year ended December 31, 2025, an 81% increase from the prior year.
• Cash used in operating activities increased to $8,237,012 in 2025 from $6,876,479 in 2024.
• The company recognized an unrealized loss of $771,863 on its digital assets in 2025, primarily due to a 30% drawdown of Bitcoin in Q4 2025.
• A loss on issuance of convertible debt of $1,490,278 was recognized in 2025 because the fair value of warrants and conversion features exceeded the principal debt amount.
• The company incurred a realized loss of $117,136 on the sale of its entire residential mortgage loan portfolio to a related party.
• The GBB Drink Lab litigation is ongoing, with the court reserving ruling on the company's summary judgment motion and the trial previously set for January 2026 being continued.
• A class action lawsuit was filed by a shareholder, Paul Durkacz, alleging stock manipulation and significant harm to investors between January 2021 and October 2025.
• The company's investment in cryptocurrencies, while diversified, introduces significant volatility and regulatory uncertainty, directly impacting financial statements.
• The company's psychedelic drug development program (Lucid-PSYCH) remains on hold due to funding prioritization strategies.
• The development of the Alcohol Misuse Healthcare Product is dependent on obtaining approximately $10,998,811 in requisite funding, with no assurance of securing it.

Risks

• Drug development is a highly uncertain undertaking with no guarantee of product sales or profitability, and the effectiveness of Lucid-MS is not yet known.
• Inability to obtain or maintain regulatory approval for Lucid-MS or other product candidates in a timely manner, or receiving approval with limiting terms.
• Reliance on licensing partners (Unbuzzd and Celly U.S.) for the commercialization of the unbuzzd retail product, with limited control over their marketing and commercialization strategy.
• Inability to raise the capital necessary to execute the company's strategy on favorable terms or at all, potentially leading to curtailment or cessation of R&D activities.
• Failure of clinical trials to demonstrate substantial evidence of safety and/or effectiveness of product candidates, or results of earlier studies not being predictive of future trials.
• Product candidates could be associated with undesirable side effects, delaying or halting clinical development, preventing regulatory approval, or leading to negative consequences.
• Significant competition for Lucid-MS from major pharmaceutical and biotechnology companies, with the possibility of competitors developing safer, more advanced, or more effective therapies.
• Reliance on single-source suppliers for drug substances and products, with potential for manufacturing problems, delays, or adverse effects on business.
• The FDA, Health Canada, or other regulatory authorities may not accept data from trials conducted in foreign jurisdictions, requiring additional costly and time-consuming trials.
• Inability to obtain and maintain sufficient intellectual property protection for product candidates, or third-party claims of intellectual property infringement.
• If the confidentiality of trade secrets, trademarks, or trade names is not adequately protected, the value of technology and business could be adversely affected.
• Investments in cryptocurrencies are subject to significant volatility, regulatory, market, and operational risks, which could materially adversely affect financial condition and results of operations.
• Cryptocurrency holdings are less liquid than cash and cash equivalents, and trading platforms may impose restrictions or become inaccessible.
• Exposure to counterparty risks with cryptocurrency custodians, including the potential for assets to be considered part of custodians' estates in insolvency proceedings.
• Uncertainty in the accounting treatment of cryptocurrency holdings under IFRS, which could require changes to financial reporting and affect investor perception.
• Cryptocurrencies are novel assets subject to ongoing uncertainty due to evolving regulatory scrutiny across the globe, potentially increasing compliance costs and affecting value.
• The company's dual-class share structure concentrates voting control with a limited number of Class A Multiple Voting Shareholders, limiting the influence of Class B Subordinate Voting Shareholders.
• Potential loss of foreign private issuer status, requiring compliance with the Exchange Act's domestic reporting regime and incurring significant expenses.
• Inability to comply with Nasdaq's continued listing standards, leading to reduced liquidity and market awareness for securities.
• Ongoing legal proceedings, including the GBB Drink Lab litigation and the CIBC/RBC spoofing lawsuit, could be costly, time-consuming, and divert management attention.
• Inability to manage growth effectively, leading to capacity constraints and pressure on internal systems and controls.
• Failure to successfully implement and maintain adequate internal controls over financial reporting or disclosure controls and procedures.
• Macroeconomic pressures, including inflation, trade policy changes, and geopolitical unrest, may materially and adversely affect business and financial results.
• The company is a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which may result in adverse U.S. federal income tax consequences for U.S. Holders.

Future Outlook

The company plans to prioritize the development of Lucid-MS, aiming for a US FDA Investigational New Drug (IND) application for a Phase 2 clinical trial in Multiple Sclerosis, with chronic toxicity studies expected to complete in Q2-Q3 2026 and drug substance/product manufacturing continuing into Q3 2026. A single Phase 2 clinical trial for Lucid-MS is planned for Q3 2026-Q4 2028. The Alcohol Misuse Healthcare Product program will undertake non-clinical activities in Q4 2026-Q3 2027, with clinical studies scheduled for Q1 2028-Q4 2029. The company intends to continue filing or acquiring additional patent applications and adapting its trial planning based on regulatory guidance and market dynamics. The company also expects to require substantial additional capital for R&D and commercialization efforts and will continue to manage its cryptocurrency treasury for financial diversification.

Management Comments

• Management believes its current financial position and recent operational improvements provide a solid foundation for operations and potential growth opportunities.
• Management views the positive Phase 1 results for Lucid-MS as a critical step that allows the company to advance clinical development and prepare for future efficacy trials in patients.
• Management believes Lucid-MS may offer advantages over therapies that primarily target the immune system in individuals with progressive MS due to its unique mechanism of action.
• Management believes there is significant demand in the market for the Alcohol Misuse Healthcare Product and that if developed, it would bring immense value to shareholders.
• Management retains full discretion to adjust cryptocurrency holdings based on market conditions and business priorities.
• Management believes the company is acting diligently and in the ordinary course to pursue and maintain its intellectual property rights.
• Management believes the company's approach mitigates many risks associated with obtaining regulatory approval for certain difficult-to-treat indications.

Industry Context

StockSavvy.ai notes that Quantum BioPharma operates in highly competitive biopharmaceutical and emerging cryptocurrency sectors. The focus on Lucid-MS for progressive multiple sclerosis positions the company against established immunomodulatory drugs like Roche's ocrelizumab and Novartis's siponimod, as well as Bruton's Tyrosine Kinase Inhibitors in Phase 3 trials. Quantum's strategy to develop a 'first-in-class, non-immunomodulatory drug' directly addressing demyelination could offer a differentiated approach in a market seeking more effective treatments for neurodegeneration. The company's foray into cryptocurrency treasury management aligns with a broader trend of corporate diversification into digital assets, though it exposes them to significant market volatility and evolving regulatory landscapes, as seen with Bitcoin, Solana, and other altcoins. The success of Unbuzzd in the consumer alcohol misuse market taps into a growing wellness trend, but its long-term viability will depend on market acceptance and competition from existing hangover remedies and emerging solutions.

Comparison to Industry Standards

• Lucid-MS, as a first-in-class, non-immunomodulatory drug, aims to differentiate from current progressive MS therapies like ocrelizumab (Roche) and siponimod (Novartis), which are immunomodulatory. This unique mechanism of action, preventing myelin degradation, could offer a significant advantage over existing treatments that primarily target the immune system.
• The positive Phase 1 MAD clinical trial results for Lucid-MS, demonstrating safety and tolerability, are a standard and necessary step for advancing drug candidates, comparable to early-stage trials conducted by other biopharmaceutical companies.
• The development of a healthcare product for alcohol misuse addresses a market need where current emergency response options are limited to vitamin drips or waiting for alcohol to wear off, suggesting a potential for a novel solution compared to existing 'hangover remedies' in the consumer market.
• The company's cryptocurrency treasury strategy, with holdings in Bitcoin, Solana, Ethereum, Sui, and Chainlink, is comparable to other companies diversifying into digital assets, but its significant proportion (41% of total assets as of December 31, 2025, and 55.86% as of March 25, 2026) is higher than many traditional corporate treasuries, exposing it to greater volatility than industry peers focused solely on fiat assets.
• The ongoing litigation against CIBC and RBC for alleged stock manipulation, seeking over $700 million, is a substantial claim, comparable in scale to other high-profile market manipulation lawsuits in the financial industry.

Management Changes

Corporate Governance

Legal Proceedings

• GBB Drink Lab Litigation: An ongoing lawsuit filed in May 2023 alleging breach of a non-disclosure agreement and misappropriation of trade secrets, with GBB claiming assets valued at US$53,047,000. The court denied the company's motion to dismiss, and later granted Joseph Romano's (former director) motion for summary judgment, dismissing claims against him. The trial, previously set for January 2026, has been continued, and the court has not yet ruled on GBB's standing to pursue claims after selling its assets.
• Dr. Raza Bokhari Litigation: All outstanding litigation with former CEO Dr. Raza Bokhari was resolved through a comprehensive settlement agreement on May 21, 2025. The company received a one-time payment of $2,350,000, and all outstanding cost awards and claims were mutually waived, eliminating future legal uncertainties.
• Lawsuit against CIBC World Markets, RBC Dominion Securities, and John Does 1-10: An ongoing lawsuit filed on October 20, 2024, in the U.S. District Court for the Southern District of New York, alleging market manipulation through 'spoofing' activities between January 2020 and August 2024. The company is seeking damages of over US$700 million. Defendants filed a motion to dismiss on June 16, 2025, and the company is awaiting the court's decision.
• Paul Durkacz Class Action Lawsuit: A class action lawsuit filed on December 22, 2025, by a shareholder alleging stock manipulation and significant harm to investors between January 6, 2021, and October 15, 2025.
• The company is subject to ongoing OSC inquiries regarding its securities trading activity and maintains an active investigation into potential market irregularities.

Related Party Transactions

• Unbuzzd and Celly U.S. Transactions: The company entered into an exclusive intellectual property license agreement with Unbuzzd (formerly Celly Nutrition Corp.) on July 31, 2023, granting rights to alcohol misuse technology for consumer products. The company also provided a loan to Unbuzzd, which was increased to C$1,300,000 as of March 31, 2024, bearing 10% interest per annum. The company maintains a 19.84% ownership interest in Unbuzzd as of December 31, 2025, and key management personnel hold three of four board positions at Unbuzzd.
• Mortgage Loan to CEO: A secured loan agreement with CEO Zeeshan Saeed for C$1,200,000 (initially) was fully repaid by Mr. Saeed on March 4, 2025.
• Sale of FSD Strategic Investments Loan Portfolio to Corporation Owned by CFO: The company sold its entire portfolio of residential mortgage loan receivables to a corporation owned by CFO Donal Carroll during 2025. The carrying amount of $2,027,730 was sold for $1,824,203 cash plus an interest receivable of $85,788, resulting in a realized loss of $117,136.
• Class A Multiple Voting Share Private Placements: Insiders (Xorax Family Trust, controlled by CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by Co-Executive Chairman Anthony Durkacz) participated in private placements of Class A Multiple Voting Shares in December 2023 (C$45.60), August 2024 (C$72.00), September 2024 (C$36.00), and December 2025 (C$750).
• 2024 Executive Bonus Settlement: Bonuses of C$450,000 each for Zeeshan Saeed, Anthony Durkacz, and Donal Carroll were settled through the issuance of 248,160 Class B Subordinate Voting Shares at C$5.44 per share in September 2024.
• 2025 Management Bonus: Accrued bonuses of C$300,000 for each of Zeeshan Saeed, Donal Carroll, and Anthony Durkacz (total C$900,000) were settled through the issuance of Class B Subordinate Voting Shares in March 2026.
• 2025 Lease Agreement: The company entered into a lease agreement with Peak Corp, an entity in which a director is a family member of a senior officer, resulting in a right-of-use asset of $102,320.
• March 2026 Convertible Debenture Financing: Eric Hoskins, a director, subscribed for 300 debenture units for C$300,000 in the first tranche of a private placement offering.

Stakeholder Impact

• Shareholders: Experience dilution from ongoing equity issuances and convertible debt conversions. Potential for future value from CVRs tied to litigation, but also face risks from stock manipulation lawsuits and cryptocurrency volatility. Class A shareholders retain concentrated voting control.
• Employees: Benefit from share-based compensation plans (options, RSUs) and bonuses, but also subject to potential disciplinary action for policy violations.
• Customers (for Unbuzzd): Benefit from a product designed to alleviate alcohol intoxication effects, with expanded retail availability.
• Patients (for Lucid-MS): Potential for a novel, non-immunomodulatory treatment for progressive multiple sclerosis, offering hope for improved mobility and neurodegenerative decline.
• Creditors: Debt settlements and convertible debenture issuances impact creditor relationships and repayment structures. The sale of the finance receivables portfolio to a related party affects the company's asset base.
• Regulatory Authorities: Ongoing compliance with FDA, Health Canada, TGA, and SEC regulations is critical for drug development and public company operations. The whistleblower policy aims to address market integrity concerns.

Next Steps

• Advance Lucid-MS program towards a US FDA Investigational New Drug (IND) application for a Phase 2 clinical trial.
• Complete chronic toxicity studies for Lucid-MS in Q2-Q3 2026.
• Initiate a single Phase 2 clinical trial for Lucid-MS in Q3 2026-Q4 2028.
• Undertake non-clinical activities for the Alcohol Misuse Healthcare Product in Q4 2026-Q3 2027.
• Initiate clinical studies for the Alcohol Misuse Healthcare Product in Q1 2028-Q4 2029.
• Continue to file or acquire additional patent applications for new data and programs.
• Monitor and manage cryptocurrency holdings based on market conditions and business priorities.
• Pursue the ongoing lawsuit against CIBC World Markets, RBC Dominion Securities, and others for alleged stock manipulation.
• Seek shareholder approval for the non-brokered private placement of Class A multiple voting shares.
• Continue to offer and sell Class B Subordinate Voting Shares through the at-the-market offering program with Rodman & Renshaw LLC.
• Complete the non-brokered private placement offering of convertible debenture units announced on March 11, 2026.

Key Dates

Recommendation

Quantum BioPharma presents a mixed bag of developments. The positive Phase 1 clinical trial results for Lucid-MS and the significant settlement in the Raza Bokhari litigation are favorable. However, the substantial net loss, increased cash burn, and the inherent volatility and regulatory uncertainty associated with its growing cryptocurrency treasury and ongoing stock manipulation lawsuits introduce considerable risk. While the long-term potential of Lucid-MS is promising, the company's financial position and reliance on future capital raises, coupled with the speculative nature of its crypto investments, suggest a 'hold' recommendation. Investors should monitor progress in clinical trials, the outcome of major litigation, and the stability of its cryptocurrency holdings before making further investment decisions.

Keywords

Biopharmaceutical, Multiple Sclerosis, Lucid-MS, Drug Development, Clinical Trials, Alcohol Misuse, Unbuzzd, Cryptocurrency, Bitcoin, Solana, Ethereum, SEC Filing, Financial Results, Litigation, Intellectual Property, Corporate Governance, Capital Raise, Neurodegenerative, Inflammatory, Metabolic Disorders